Roche's Anaemia Therapies to Feature Strongly at Upcoming World Congress of Nephrology

Basel, Switzerland (ots/PRNewswire) - Nephrologists attending the
upcoming World Congress of Nephrology (WCN) in Rio de Janeiro, Brazil
21-25 April will hear about a wide range of study results from
Roche's robust renal anaemia clinical trial programs for its two
treatments -- MIRCERA(R) and NeoRecormon(R).

Among the highlights will be two analyses on MIRCERA, Roche's new
continuous erythropoietin receptor activator that is awaiting
regulatory approval worldwide. The oral and poster presentations
review MIRCERA's once monthly haemoglobin stability in the dialysis
setting with different patient populations; and new safety data which
shows the rate of haemoglobin decline after withholding once monthly
MIRCERA treatment.

Eight posters feature results from trials with Roche's first
anaemia drug, NeoRecormon. Highlights include further results from
the GAIN trial, an observational, prospective study assessing the
management of renal anaemia in more than 4,000 haemodialysis patients
within everyday clinical practice in 13 European countries; three
posters from the IRIDIEM study investigating anaemia management in
chronic kidney disease patients with Type 2 diabetes and three
posters discussing the preliminary results from the ORAMA study,
which used a guideline-based computerized system for clinical
decision making.

Details of the study results will be available concurrent with
when they are presented at the congress. Please note all information
presented at the annual meeting is embargoed for media release until
the time of presentation.

Author Abstract Title Presentation Date & Time of
Type Presentation
MIRCERA Presentations
Author: M. Heifets and Hemoglobin (Hb) Poster Sunday, 22 April
F. Dougherty Decline After 2007
Withholding C.E.R.A.
Administration is not
Influenced by
C.E.R.A.'s Long Half
Life.
Author: R. Bernardo C.E.R.A. Administered Oral Monday, 23 April
Once Monthly 2007
Maintains Stable Hb
Levels in Patients
with CKD on Dialysis
Regardless of Age and
Gender.
NeoRecormon
Presentations
Author: A. Weinreich Effectiveness and Poster Sunday, 22 April
safety of haemoglobin 2007
management with
epoetin beta -
results from the
12-month follow-up
period of GAIN.
Author: A. Covic Achievement of EBPG Poster Monday, 23 April
targets in Eastern 2007
and Western Europe:
ORAMA preliminary
results.
Author: I. MacDougall Does a guideline Poster Monday, 23 April
based computerized 2007
clinical decision
support system
improve Hb
attainment? - ORAMA
preliminary results.
Author: A. Winkler Treatment of renal Poster Monday, 23 April
anaemia in clinical 2007
practice taking into
account the "European
Best Practice
Guidelines" (EBPG)
supported by a new
computer based system
(CDS).
Author: P. Stevens Cardiovascular Poster Tuesday, 24
comorbidity and April 2007
medicines management
in 1154 patients with
type 2 diabetes and
CKD: The IRIDIEM
survey.
Author: P. Stevens Anaemia management in Poster Tuesday, 24
1154 patients with April 2007
type 2 DM & CKD: A
snapshot of Europe
from the IRIDIEM
survey.
Author: C. Wanner Epidemiology, Poster Tuesday, 24
associated April 2007
comorbidities and
treatment management
in elderly patients
with CKD and type 2
diabetes mellitus.
NeoRecormon Presentations Continued
Author: P.M. Wee Immediate pain Poster Time - To be
sensation is less Announced
with s.c. NeoRecormon
compared to s.c.
Aranesp

Interested journalists may view the meeting schedule online at
http://www.wcn2007.org.

For more information, please contact:

Sheila Gies at Roche

Tel: +973-235-4347

Mobile: +973-687-0188

Abenaa Hayes at Weber Shandwick

Tel: +212-445-8337

Mobile: +646-418-7224

ots Originaltext: Roche Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Sheila Gies at Roche, Tel: +973-235-4347, Mobile: +973-687-0188,
Abenaa Hayes at Weber Shandwick, Tel: +212-445-8337, Mobile:
+646-418-7224